Antioxidants in Kidney Diseases: The Impact of Bardoxolone Methyl
Drugs targeting the renin-angiotensin-aldosterone system (RAAS) are the mainstay of therapy to retard the progression of proteinuric chronic kidney disease (CKD) such as diabetic nephropathy. However, diabetic nephropathy is still the first cause of end-stage renal disease. New drugs targeted to the...
Saved in:
Main Authors: | Jorge Rojas-Rivera, Alberto Ortiz, Jesus Egido |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2012-01-01
|
Series: | International Journal of Nephrology |
Online Access: | http://dx.doi.org/10.1155/2012/321714 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Phosphorus and Nutrition in Chronic Kidney Disease
by: Emilio González-Parra, et al.
Published: (2012-01-01) -
Bisphenol A in Chronic Kidney Disease
by: Emilio González-Parra, et al.
Published: (2013-01-01) -
Methylation-Demethylation Dynamics: Implications of Changes in Acute Kidney Injury
by: Anubhav Chakraborty, et al.
Published: (2018-01-01) -
TNF Superfamily: A Growing Saga of Kidney Injury Modulators
by: Maria D. Sanchez-Niño, et al.
Published: (2010-01-01) -
Serotonin and Its Receptor as a New Antioxidant Therapeutic Target for Diabetic Kidney Disease
by: Yu Yang, et al.
Published: (2017-01-01)